NOT FOR PUBLICATION

COMMERCIAL IN CONFIDENCE

COMMITTEE ON SAFETY OF MEDICINES

SUB-COMMITTEE ON BIOLOGICAL PRODUCTS

Minutes of the meeting held on 7 March 1984

PRESENT	ALSO PRESENT	
Dr J.W.G. Smith (Chairman)	Dr F.W. Sheffield)	
Professor J.G. Collee	Dr M. Spitz)	NIBSC
Professor G.C. Jenkins	Dr E. Griffiths)	
Professor H. Keen	Dr J. Brindley-Morgan	MAFF
Professor J. Melling	Mr K.J. Ayling	
Dr D.P. Thomas	Dr J. Barnes	
Dr D.A.J. Tyrrell	Mr J.P. Betts	
Mr J.G. Watt	Dr M.E. Duncan	
Dr R. Mann (Medical Assessor)	Dr L.K. Fowler	
Dr J. Purves (Pharmaceutical Assessor)	Mr J. Grimshaw	
Mr H.M. Morgan (Secretary)	Mr T.J. Kirkley	
	Mr G. Wade	

1. Confidentiality and Announcements

The Chairman welcomed Professor Collee who was attending the meeting for the first time. He also welcomed Dr Mann, who had recently been appointed Medical Assessor to the Sub-Committee, and Mr Grimshaw, who recently became Secretary to the CSM.

The Chairman reminded members that the material they received was confidential and should not be disclosed outside the meeting. He also reminded members that any interest in applications under consideration should be declared before they were discussed by the Sub-Committee.

2. Apologies for absence

An apology for absence had been received from Dr Lane.

3. Minutes of the meeting held on 4 January 1984

These were agreed and signed by the Chairman as a correct record of the proceedings.

4. Matters arising from the minutes

The Sub-Committee noted the CSM's advice on applications previously considered by the Sub-Committee. The Chairman drew member's attention to the CSM's advice on the applications for Solcotrichovac and Berofor Nasal Spray.

The Sub-Committee had recommended the issue of a clinical trial certificate for Berofor Nasal Spray, as had the CPS Sub-Committee, both with a number of conditions. The CSM had considered that there were too many conditions for the professional Secretariat to clear with the Company within a reasonable time period.

In respect of Solcotrichovac, CSM had asked SEAR to consider the application, particularly with respect to the clinical trial data. SEAR had considered that further clinical trial evidence of safety and efficacy was required, a view which CSM had endorsed.

CSM had advised that Section 21(1) action should be taken on both applications.

5. Consideration of applications

5.1 PL/3070/0007 - Speywood Industries - Hyate:C

5.2 PL/0086/0100 - Hoechst UK Ltd - Factor VIII HS

5.3 PL/0022/0056 - KabiVitrum Ltd - Gammonativ

The Sub-Committee's recommendations on these applications are at appendices A-C.

6. Written representation

PL/0093/0046-7 - Servier Laboratories Ltd - Tetavax.

The Sub-Committee's recommendation on this written representation is at appendix D.

7. Paper : Consideration for the Standardization and Control of the New Generation of Biological Products

The Sub-Committee endorsed this paper, which had been prepared by NIBSC, and recommended that it be presented for consideration by CSM at their next meeting.

8. Item for information - MAIL 39

This was circulated to members for their information.

9. Any other business

None.

10. Date and time of next meeting

Wednesday, 2 May 1984 at 10.30 a.m.

GRO-C

GRO-C

4/2/84

No.

PL/0086/0100

Coy.

Hoechst UK Ltd

Product

Factor VIII H.S

Therapeutic Class

Antihaemophilic

Active Constituent

Factor UIII
250 IU,
500 IU,
1000 IU per vial

SUB-COMMITTEE ON BIOLOGICAL PRODUCTS — 7 MARCH 1984

RECOMMENDATION

On the evidence before them the Sub-Committee recommended the grant of a Product Licence on condition that:

1. satisfactory information was provided on the heat-treatment process; this should include the identity and concentrations of added stabilising agents,

2. clarification was given on the electrophoresis data before and after heating, with special reference to the thermal degradation products of Factor VIII and clear statements were given on the change in Factor VIII potency,

3. the Finished Product Specification was amended to include:-

   i) a test with suitable limits for sodium,

   ii) a clear statement of the acceptance/rejection criteria in the microzone electrophoresis test,

   iii) an upper limit of Factor VIII activity of not more than 125% of the labelled amount.

4. suitable comparative results between the Behringwerke assay for Factor VIII and the BP 1980 assay was provided, together with confirmation that the Behringwerke standard is calibrated in IU against the WHO International Standard,

5. additional stability data were provided showing the results of tests for degradation products on storage,

6. confirmation was given that the air in the vial is removed or replaced by sterile oxygen free nitrogen,

7. an assurance was given that the Albumin would comply, if tested, with all the tests in the BP specification,

8. biological evidence of the reproducibility of the inactivation process was provided,

9. the Data Sheet and Product Particulars were amended to the satisfaction of the Secretariat, with particular reference to:

   i) inclusion of a statement that the material was heat-treated;

   ii) no claims were made that the transmission of hepatitis B and non-A non-B hepatitis had been excluded;

   iii) no reference to AIDS was included except as a warning that blood products may transmit the syndrome,

No.

PL/0086/0100

Coy.

Hoechst UK Ltd

Product

Factor VIII H.S

Therapeutic Class

Antihaemophilic

Active Constituent

Factor UIII
250 IU,
500 IU,
1000 IU per vial

10. the Batch Release procedure should apply, to include the provision of bulks and in-process samples.

Remark

Further studies on the effectiveness of the inactivation process should be undertaken.